
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics is currently attractively valued with a BUY rating, and the 12-month price target has been raised to $9.50 due to a strong NPV analysis. The potential high risks associated with the development of their flagship drug, Stenoparib, are outweighed by the company's overall growth prospects and valuation. These risks are balanced out by the potential for significant upside opportunities in the future.
Bears say
Allarity Therapeutics is a clinical-stage biopharmaceutical company that operates with minimal revenue and generates high net losses. Although the company has a promising drug in development, Stenoparib, for ovarian and small cell lung cancer, its financials and lack of revenue generation raise concerns about its ability to successfully bring the drug to market and achieve profitability in the future. The company's reliance on its DRP technology and the highly competitive PARP inhibitor market also add to the negative outlook.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares